Analyst Price Targets — NVCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 11:04 am | — | H.C. Wainwright | $47.00 | $13.74 | TheFly | Novocure price target raised to $47 from $39 at H.C. Wainwright |
| January 13, 2026 11:03 am | — | H.C. Wainwright | $39.00 | $14.18 | TheFly | Novocure price target lowered to $39 from $42 at H.C. Wainwright |
| January 5, 2026 2:54 pm | — | Evercore ISI | $20.00 | $13.71 | TheFly | Novocure price target lowered to $20 from $22 at Evercore ISI |
| October 30, 2025 4:11 pm | — | H.C. Wainwright | $42.00 | $13.18 | TheFly | Novocure price target raised to $42 from $38 at H.C. Wainwright |
| July 24, 2025 8:09 pm | Larry Biegelsen | Wells Fargo | $14.50 | $12.54 | TheFly | Novocure downgraded to Equal Weight from Overweight at Wells Fargo |
| December 2, 2024 11:00 am | Vijay Kumar | Evercore ISI | $30.00 | $26.43 | StreetInsider | Evercore ISI Upgrades NovoCure Ltd. (NVCR) to Outperform 'into Panova readout on asymmetric risk/reward' |
| October 16, 2024 6:06 am | Emily Bodnar | H.C. Wainwright | $30.00 | $17.78 | StreetInsider | H.C. Wainwright Upgrades NovoCure Ltd. (NVCR) to Buy |
| July 26, 2024 6:48 am | Emily Bodnar | H.C. Wainwright | $24.00 | $18.26 | StreetInsider | NovoCure Ltd. (NVCR) PT Raised to $24 at H.C. Wainwright |
| May 3, 2024 6:46 am | Emily Bodnar | H.C. Wainwright | $22.00 | $14.19 | StreetInsider | NovoCure Ltd. (NVCR) PT Lowered to $22 at H.C. Wainwright |
| May 2, 2024 4:48 pm | Vijay Kumar | Evercore ISI | $14.50 | $14.78 | StreetInsider | NovoCure Ltd. (NVCR) PT Lowered to $14.50 at Evercore ISI |
Latest News for NVCR
Explore NovoCure's (NVCR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country's National Health Insurance coverage. Optune Lua is approved in Japan for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy.…
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 2026 Leerink Global Healthcare Conference.
NovoCure (NVCR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.61 per share a year ago.
NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NVCR.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.